SEC Form 4 · accession 0001140361-26-035609

Apogee Therapeutics, Inc. · APGE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Sep 3, 2026

Accepted (ET)

Sep 3, 2026 · 4:39 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001974640

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Sep 3, 2026	D	920,941	—	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option (Right to Buy)^F3,F2	$22.86	Sep 3, 2026	D	387,012	D	—	Dec 18, 2033	Common Stock	387,012	D
Stock Option (Right to Buy)^F3,F2	$49.07	Sep 3, 2026	D	357,036	D	—	Dec 9, 2034	Common Stock	357,036	D
Stock Option (Right to Buy)^F3,F2	$75.78	Sep 3, 2026	D	253,016	D	—	Jan 2, 2036	Common Stock	253,016	D

F1The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the "Merger Agreement"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc.
F2The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger.
F3Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option.